Contract notice: Pharmaceutical products Tender, Germany - 34977994

Procurement Summary

Country : Germany

Summary : Contract notice: Pharmaceutical products

Deadline : 05 Jul 2021

Other Information

Notice Type : Tender

TOT Ref.No.: 34977994

Document Ref. No. : 349062-2019

Competition : ICB

Financier : Self Financed

Purchaser Ownership : -

Tender Value : Refer Document

Purchaser's Detail

Name :Login to see tender_details

Address : Login to see tender_details

Email : Login to see tender_details

Login to see details

Tender Details

Object of the contract
Pharmaceutical products

Description: Contract notice: Pharmaceutical products

Authority Type: Body governed by public law
Contact Nature: Supplies
Procedure: Open procedure
Document: Contract notice
Regulation: European Union
Award criteria: Lowest price
CPV code: 33600000, 33600000
CPV Description: Pharmaceutical products.

Conclusion of a non-exclusive rebate agreement pursuant to Section 130a (8) SGB V on the active substance olmesartan, amlodipine and hydrochlorothiazide, ATC C09Dx03, for the period 1.9.2019 31.8.2021

Reference Number: 1002688 - Olmesartan, amlodipine and hydrochlorothiazide

- 130a paragraph 8 SGB V allows the health insurance companies and pharmaceutical companies, Rahmenrabattvertraege over die exclude medicinal products to be surrendered to the statutory health insurance funds. In view of the pertinent statutory provisions on the awarding of public contracts, a regular process of active substance-based, public procurement procedures takes place in accordance with the regulations of the 4th part of the GWB by DAK-Gesundheit. For the bidder closer in Appendix 2 to the contract to benaming drugs to the o. g. The active substance (olmesartan, amlodipine and hydrochlorothiazide) is intended for DAK-Gesundheit to conclude a drug discount agreement with as many pharmaceutical companies as possible until new pharmaceutical rebates enter into force. A discount contract i.r.d. Approval model for the o. G. Active ingredient enters into force and ends on 1.9.2019 for the first timet on 31.8.2021. It will automatically terminate automatically upon entry into force of the exclusive agreement.

The DAK-G assumes that this procedure does not fall within the scope of antitrust law due to the lack of a selection decision and thus the non-discriminatory accessibility of all pharmaceutical companies. It ends automatically with inkrafttre independentlyexclusive contract for olmesartan, amlodipine and hydrochlorothiazide, C09Dx03, as a result of a public procurement procedure in accordance with the provisions of Part 4 of the GWB with one or more contractual partners. In order to cope with the diversity of the potential contractors within the framework of the approval model, each pharmaceutical company will be required to conclude a contract during the contract periodFramework Agreement at any time and under the same conditions. The contract documents required for this are available via the online portal www.dtvp.de/center under the subsection I.3. The following link is available for download.

The prerequisite for the completion or later joining of the contracts, which enter into force on 1.9.2019, is the complete and timely delivery of UebeSubmission of the following proofs / statements / attachments (available for download under the link under I.3.) to the following contact person at the DAK-G:

1) Offer letter;

2) Current proof of entry in the trade or professional register (see III.1.1.)

3) Self-declaration by the company (Annex A1) that none of the exclusion criteria according to -- 123, 124 GWB exist(4) self-declaration that for those medicinal products for which the prospective buyer wishes to conclude a contract under this procedure, there is a drug license and that the tenderer is entitled to sell at the inception of the contract (Annex A2) (see III.1.1.);

5) self-declaration of the company that the statutory minimum wage requirements and tor Tariff loyalty observed and complied with (Annex A3) (see III.1.1.)

6) Recognition of the contractual obligations of DAK-health, in particular the prescribed discounts by signing the contract stamped with a company (2-fold in original (7) The completed Annexes 1 and 2 to the contract (twice each in the original). The Interessent has here the medicines to the o. g. 8) Effective pre-qualification notification of DAK health (see III.1.1 and III.1.2.)

The documents must be submitted by post to:

DAK-Gesundheit

Hr. Hien Nguyen / Hr. Jan Semler (0032 70)

Nagelsweg 27-31

20097 Hamburg

Furthermore, the attachment 2 as an Excel file is the same timeto the mail address am_rabattvertraege@dak.de. Contracts under this model and to o. G. The active substance will be concluded for the first time with effect from 1.9.2019 and will end on 31.8.2021. Interested parties wishing to become contract partners on this date have the above-mentioned documents to be submitted by the 5th of the previous month at o. G. Submit job. For the deadline is an electronischer receipt of the complete documents by e-mail to the e-mail address am_rabattvertraege@dak.de sufficient. Later accessions are possible at any time. In order to be able to join during the term of the contract on the 1st or 15th of the following month, the o. G. Documents, regardless of the desired accession, the DAK-health until the 5th of the previous month. Again, it comeson the timely access of both DAK-G. Example: The applicant`s wish to join will be 15.07.20x (following month), the documents must be there by 05.06.20x (previous month).

Note: The publication takes place here using the form for open procedures. As already made clear, this is not one - the noticehad to be used for technical reasons, as there is no form suitable for registration procedures.

1) Current proof of registration in the professional or commercial register (not older than 6 months on dispatch) in accordance with the legislation of the country in which the company is established is, for. Eg current commercial register extract; Copy is sufficient.

2) Self-declaration of theCompany, that none of the exclusion criteria according to -- 123, 124 GWB exists. Attachment A1 must be signed, stamped and submitted in original.

3) Self-declaration that for those medicines for which the prospective buyer wishes to conclude a contract under this procedure, there is a drug license and that Bieter is entitled to distribution at the beginning of the contract (Annex A2) (see III.1.1.).

4) Self-declaration by the company that the legal requirements on minimum wage and tariff fidelity are complied with and adhered to (Annex A3). To this end, the annex A3 is to be signed, provided with the company stamp and submitted in the original.

DAK-Gesundheit has the European announcement platforma so-called pre-qualification procedure for pharmaceutical companies for the simplified participation in future drug rebates published (EU Announcement 2015 / S 105-190319 of 3.6.2015). If the bidder has received an effective pre-qualification notification from DAK-Gesundheit in good time before submission of the documents, he needs the company-specific eggproof of registration in the trade or professional register, self-declaration of the company, that none of the exclusion criteria according to -- 123, 124 GWB is present, certificate of public health insurance) with reference and enclosing the Praequalifikationsbescheides in copy no longer to be attached. Attachment A2 must always be attached. The PraequalifikatiDeclaration of DAK-Health also serves as proof in open-house procedures of DAK-Health, regardless of the order value.

Self-declaration that for those medicines for which the prospective customer wishes to conclude the contract in the context of this procedure, a drug approval and that the tenderer is entitled to distribute at the beginning of the contractis. Attachment A2 has to be signed, stamped and submitted in original. DAK-Gesundheit has published a so-called pre-qualification procedure for pharmaceutical companies for the simplified participation in future drug rebate tenders via the European Announcement Platform (EU Announcement 2015 / S 105-190319 of 3.6.2015). SoIf the bidder has received an effective pre-qualification notification from DAK-Gesundheit in good time before the submission of the documents, he needs the company-specific proof of suitability (proof of registration in the trade or professional register, self-declaration by the company that none of the exclusion criteria according to -- 123, 124 GWB is present, clearance certificate of lawchen Krankenkasse) with reference and addition of the Praequalifikationsbescheides in copy no longer be enclosed. Attachment A2 must always be attached. The pre-qualification notification from DAK-Gesundheit also serves as proof in open-house procedures of DAK-Gesundheit.

The tender documents can also be sent by e-mail in the case I.1. contact mentionedbe requested. The tender documents will then be sent by e-mail.

Questions and information on the tender documents are available electronically (via the bidder communication via the allocation portal dtvp.de) or in necessary individual cases by e-mail or in writing (by fax or letter) to the under I.1. to be addressed. They are in German zu formulate. Answers will be made available to all entrepreneurs who have requested the tender documents by means of a registration in anonymous form. The answers are provided to the entrepreneurs by means of bidder communication via the allocation portal dtvp.de. Companies that have downloaded the tender documents without registration, have in eiResponsible to pursue the further communication and, if necessary, to the o. g. This publication does not constitute a public service contract within the meaning of the 2014/24 / EU Procurement Coordination Directive of the European Parliament and of the Council or of the Public Procurement Law. To a maximum degree of transparency for the beabto ensure the conclusion of contracts, it shall be published in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process name "Open Procedure", are solely the use of this announcement formand the publication platform owed. A further meaning, in particular a submission under public procurement regulations, as far as they are not obligatory for legal reasons, is not connected with this.

Announcement ID: CxP4YM5YTW9


Internet address (URL): www.dak.de

Documents

 Tender Notice